You just read:

Boehringer Ingelheim Announces Completed Enrollment of Phase III Clinical Trial for Biosimilar Candidate to Adalimumab

News provided by

Boehringer Ingelheim Pharmaceuticals, Inc.

Nov 10, 2015, 08:30 ET